HRP20100591T1 - Smjese za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije - Google Patents
Smjese za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije Download PDFInfo
- Publication number
- HRP20100591T1 HRP20100591T1 HR20100591T HRP20100591T HRP20100591T1 HR P20100591 T1 HRP20100591 T1 HR P20100591T1 HR 20100591 T HR20100591 T HR 20100591T HR P20100591 T HRP20100591 T HR P20100591T HR P20100591 T1 HRP20100591 T1 HR P20100591T1
- Authority
- HR
- Croatia
- Prior art keywords
- sodium
- mixture
- sulbactam
- ceftriaxone
- amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 25
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims abstract 5
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims abstract 5
- 108090000204 Dipeptidase 1 Proteins 0.000 title claims abstract 4
- 102000006635 beta-lactamase Human genes 0.000 title claims abstract 4
- 230000001404 mediated effect Effects 0.000 title claims abstract 4
- 230000003115 biocidal effect Effects 0.000 title claims abstract 3
- 238000002347 injection Methods 0.000 title claims abstract 3
- 239000007924 injection Substances 0.000 title claims abstract 3
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 claims abstract 13
- 229960000479 ceftriaxone sodium Drugs 0.000 claims abstract 13
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims abstract 13
- 229960000614 sulbactam sodium Drugs 0.000 claims abstract 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract 8
- 229960004755 ceftriaxone Drugs 0.000 claims abstract 8
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims abstract 8
- 229960005256 sulbactam Drugs 0.000 claims abstract 8
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 2
- 229940088710 antibiotic agent Drugs 0.000 claims abstract 2
- 239000002738 chelating agent Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 12
- 229910052708 sodium Inorganic materials 0.000 claims 12
- 239000011734 sodium Substances 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000008215 water for injection Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000011261 inert gas Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000011049 filling Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000008228 bacteriostatic water for injection Substances 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229910052756 noble gas Inorganic materials 0.000 claims 1
- 150000002835 noble gases Chemical class 0.000 claims 1
- 238000012859 sterile filling Methods 0.000 claims 1
- 239000008227 sterile water for injection Substances 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Farmaceutska smjesa za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike, koja upotrebljava inhibitor beta-laktamaze, naznačena time, što sadrži: a) beta-laktamski antibiotik ceftriakson ili njegovu farmaceutski prihvatljivu sol, b) inhibitor beta-laktamaze sulbaktam ili njegovu farmaceutski prihvatljivu sol gdje su spojevi dijela (a) i dijela (b) pomješani u težinskom omjeru od 1:4 do 4:1, poželjno od 1:3 do 3:1, poželjnije 2:1 do 1:2, (c) inhibitor formiranja čestica koji je aminokarbonsko-kiselinsko helirajuće sredstvo, koje je EDTA ili njegova farmaceutski prihvatljiva sol, u opsegu od 0.002 mg/ml do 10 mg/ml, poslije rekonstitucije, igdje je spomenuta smjesa fiksna dozna kombinacija koja se primjenjuje parenteralno poslije rekonstituiranja sa volumenom vodene otopine odabrane između sterilne vode za injekcije, bakteriostatske vode za injekcije i izotonične sterilne otopine natrijeva klorida, gdje spomenuta smjesa dalje sadrži farmaceutski prihvatljivo sredstvo za podešavanje toničnosti koje smjesi daje fiziološku izotoničnost, odabrano iz grupe koja sadrži natrijev klorid i dekstrozu, spomenuto sredstvo za toničnost je prethodno pomiješano sa smjesom, ili upotrebljeno tokom spomenute rekonstitucije, ili alternativno u vrijeme infuzije. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Farmaceutska smjesa za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike, koja upotrebljava inhibitor beta-laktamaze, naznačena time, što sadrži:
a) beta-laktamski antibiotik ceftriakson ili njegovu farmaceutski prihvatljivu sol,
b) inhibitor beta-laktamaze sulbaktam ili njegovu farmaceutski prihvatljivu sol gdje su spojevi dijela (a) i dijela (b) pomješani u težinskom omjeru od 1:4 do 4:1, poželjno od 1:3 do 3:1, poželjnije 2:1 do 1:2,
(c) inhibitor formiranja čestica koji je aminokarbonsko-kiselinsko helirajuće sredstvo, koje je EDTA ili njegova farmaceutski prihvatljiva sol, u opsegu od 0.002 mg/ml do 10 mg/ml, poslije rekonstitucije, i
gdje je spomenuta smjesa fiksna dozna kombinacija koja se primjenjuje parenteralno poslije rekonstituiranja sa volumenom vodene otopine odabrane između sterilne vode za injekcije, bakteriostatske vode za injekcije i izotonične sterilne otopine natrijeva klorida, gdje spomenuta smjesa dalje sadrži farmaceutski prihvatljivo sredstvo za podešavanje toničnosti koje smjesi daje fiziološku izotoničnost, odabrano iz grupe koja sadrži natrijev klorid i dekstrozu, spomenuto sredstvo za toničnost je prethodno pomiješano sa smjesom, ili upotrebljeno tokom spomenute rekonstitucije, ili alternativno u vrijeme infuzije.
2. Smjesa prema zahtjevu 1, naznačena time, što je:
a) ceftriakson prisutan u vidu svoje natrijeve soli, i
b) sulbaktam je prisutan u vidu svoje natrijeve soli.
3. Smjesa prema zahtjevu 1 ili 2, naznačena time, što je ukupan sadržaj natrija u spomenutoj fiksnoj doznoj kombinaciji u opsegu od 16.5 mg (0.719 mEq) do 264.6 mg (11.48 mEq) natrija i prisutan je u farmaceutski efikasnoj količini koja odgovara 1 do 10 jediničnih doza, u graduiranom kontejneru.
4. Smjesa zahtjevana u bilo kojem od zahtjeva 1 do 3, naznačena time, što sadrži:
(a) ceftriakson natrij u količini od , preračunato kao ceftriaksonska slobodna kiselina,
(b) sulbaktam natrij u količini od , preračunato kao sulbaktamska slobodna kiselina, i
(c) EDTA u količini od 2 mg,
spomenuta smjesa je rekonstituirana sa 20 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 264,6 mg, uz 11.48 mEq natrija.
5. Smjesa zahtjevana u bilo kojem od zahtjeva 1 do 3, naznačena time, što sadrži:
(a) ceftriakson natrij u količini od , preračunato kao ceftriaksonska slobodna kiselina,
(b) sulbaktam natrij u količini od , preračunato kao sulbaktamska slobodna kiselina, i
(c) EDTA u količini od 1 mg,
spomenuta smjesa je rekonstituirana sa 10 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 132.3 mg, uz 5.74 mEq natrija.
6. Smjesa zahtjevana u bilo kojem od zahtjeva 1 do 3, naznačena time, što sadrži:
(a) ceftriakson natrij u količini od , preračunato kao ceftriaksonska slobodna kiselina,
(b) sulbaktam natrij u količini od , preračunato kao sulbaktamska slobodna kiselina, i
(c) EDTA u količini od 0.5 mg,
spomenuta smjesa je rekonstituirana sa 5 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 66.15 mg, uz 2.87 mEq natrija.
7. Smjesa zahtjevana u bilo kojem od zahtjeva 1 do 3, naznačena time, što sadrži:
(a) ceftriakson natrij u količini od , preračunato kao ceftriaksonska slobodna kiselina,
(b) sulbaktam natrij u količini od , preračunato kao sulbaktamska slobodna kiselina, i
(c) EDTA u količini od 0.25 mg,
spomenuta smjesa je rekonstituirana sa 4 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 33.075 mg, uz 1.435 mEq natrija.
8. Smjesa zahtjevana u bilo kojem od zahtjeva 1 do 3, naznačena time, što sadrži:
(a) spomenuti ceftriakson natrij u količini od , preračunato kao ceftriaksonska slobodna kiselina,
(b) spomenuti sulbaktam natrij u količini od , preračunato kao sulbaktamska slobodna kiselina, i
(c) spomenuti EDTA prisutan u količini od 0.125 mg, spomenuta smjesa je rekonstituirana sa 2 ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznosi 16.535 mg, uz 0.717 mEq natrija.
9. Smjesa zahtjevana u bilo kojem od zahtjeva 1 do 8 pakovana i zapečaćena u sterilnom kontejneru pod pokrovom od inertnog plina, naznačena time, što spomenuti kontejner predstavljaju jedna ili više fiola, ampula, šprica, paketića, fišeka i auto-injektora, gdje unutrašnji prostor spomenutog kontejnera obuhvaća volumen za punjenje zauzetu spomenutom smjesom u rekonstituiranoj formi i volumen vršnog dijela aseptički zauzet mikroatmosferom limitiranom inertnim plinom, koja uključuje suštinski jedan ili više inertnih plinova odabranih iz grupe koja sadrži plemenite plinove i dušik, poželjno dušik, volumen spomenutog plinovitog dušika nije veći od 5% od spomenutog volumena vršnog dijela, i gdje odnos spomenutog volumena za punjenje prema spomenutom volumenu vršnog dijela nije manji od 1:1
10. Postupak za pripremanje smjese za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike koja koristi inhibitor beta-laktamaze, korisne za injekcije, spremne za farmaceutsku primjenu, naznačen time, što uključuje korake:
(a) sterilno punjenje/miješanje dva aktivna sastojka, prvi aktivni sastojak je ceftriakson natrij, a drugi sastojak je sulbaktam natrij,
(b) dodavanje inhibitora formiranja čestica koji je etilendiamin-tetraoctena kiselina dinatrijeva sol,
(c) kontinuirano spomenuto sterilno miješanje tokom perioda u opsegu od 1 sata do 4 sata,
(d) odmjeravanje sterilne mješavine iz koraka (a), aseptično, da bi se dobila željena doza u nekom od težinskih odnosa iz zahtjeva 1, i
(d) ) aseptično zatvaranje uz pre-post uvođenje inertnog plina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2411DE2004 | 2004-12-02 | ||
| PCT/IN2005/000382 WO2006059344A1 (en) | 2004-12-02 | 2005-11-28 | Compositions for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitors useful for injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100591T1 true HRP20100591T1 (hr) | 2010-12-31 |
Family
ID=35789266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100591T HRP20100591T1 (hr) | 2004-12-02 | 2010-11-03 | Smjese za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8273732B2 (hr) |
| EP (1) | EP1841432B1 (hr) |
| JP (1) | JP5269415B2 (hr) |
| KR (2) | KR20070067189A (hr) |
| CN (1) | CN101060846A (hr) |
| AT (1) | ATE476981T1 (hr) |
| AU (1) | AU2005310888B2 (hr) |
| BR (1) | BRPI0517128A (hr) |
| CY (1) | CY1110886T1 (hr) |
| DE (1) | DE602005022939D1 (hr) |
| DK (1) | DK1841432T3 (hr) |
| ES (1) | ES2349301T3 (hr) |
| HR (1) | HRP20100591T1 (hr) |
| MX (1) | MX2007006540A (hr) |
| NZ (1) | NZ555075A (hr) |
| PL (1) | PL1841432T3 (hr) |
| PT (1) | PT1841432E (hr) |
| RS (1) | RS51506B (hr) |
| RU (1) | RU2397768C2 (hr) |
| SI (1) | SI1841432T1 (hr) |
| UA (1) | UA91204C2 (hr) |
| WO (1) | WO2006059344A1 (hr) |
| ZA (1) | ZA200704394B (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030010176A (ko) * | 2001-07-25 | 2003-02-05 | 이병두 | 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| CN101537009B (zh) * | 2009-04-30 | 2010-09-15 | 海口奇力制药股份有限公司 | 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| RU2593363C2 (ru) * | 2011-05-28 | 2016-08-10 | Вокхардт Лимитед | Композиции, включающие антибактериальное средство и тазобактам |
| JP5809750B2 (ja) * | 2011-07-26 | 2015-11-11 | ウォックハート リミテッド | β−ラクタム抗生物質、スルバクタム及びβ−ラクタマーゼ阻害薬を含む医薬組成物 |
| WO2013042140A2 (en) * | 2011-09-23 | 2013-03-28 | Manu Chaudhary | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| MY169816A (en) | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| RU2650962C2 (ru) | 2012-06-07 | 2018-04-18 | Чилдрен'З Хоспитал Лос Анджелес | Способы лечения нейтропении с применением ретиноидных агонистов |
| US20150306076A1 (en) * | 2012-09-27 | 2015-10-29 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
| EP3107533A4 (en) | 2014-02-18 | 2017-10-18 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
| JP2017508769A (ja) * | 2014-03-29 | 2017-03-30 | ウォックハート リミテッド | セフェピムまたはスルバクタムを含む医薬組成物 |
| CN106456441A (zh) * | 2014-04-03 | 2017-02-22 | 丘比株式会社 | 注射液用袋及注射用制剂 |
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| EP3429592A4 (en) * | 2016-11-02 | 2019-10-30 | Xiangbei Welman Pharmaceutical Co., Ltd | COMPOSITION COMPOSED OF CEFTRIAXONE SODIUM AND SULBACTUM SODIUM |
| CN106822147B (zh) * | 2016-11-03 | 2021-07-20 | 湘北威尔曼制药股份有限公司 | 一种头孢曲松钠和舒巴坦钠组合物、包含该组合物的药物制剂及其应用 |
| RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630510B1 (en) * | 1999-10-28 | 2003-10-07 | Merck & Co., Inc. | Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| ATE381947T1 (de) * | 2003-04-14 | 2008-01-15 | Wyeth Corp | Zusammensetzungen enthaltend piperacillin und tazobactam zur injektion |
-
2005
- 2005-11-28 KR KR1020077010375A patent/KR20070067189A/ko not_active Application Discontinuation
- 2005-11-28 US US11/720,710 patent/US8273732B2/en not_active Expired - Fee Related
- 2005-11-28 PL PL05817957T patent/PL1841432T3/pl unknown
- 2005-11-28 JP JP2007544016A patent/JP5269415B2/ja not_active Expired - Fee Related
- 2005-11-28 ES ES05817957T patent/ES2349301T3/es active Active
- 2005-11-28 MX MX2007006540A patent/MX2007006540A/es active IP Right Grant
- 2005-11-28 BR BRPI0517128-8A patent/BRPI0517128A/pt not_active IP Right Cessation
- 2005-11-28 RU RU2007124325/15A patent/RU2397768C2/ru not_active IP Right Cessation
- 2005-11-28 SI SI200531130T patent/SI1841432T1/sl unknown
- 2005-11-28 UA UAA200707280A patent/UA91204C2/ru unknown
- 2005-11-28 EP EP05817957A patent/EP1841432B1/en active Active
- 2005-11-28 DE DE602005022939T patent/DE602005022939D1/de active Active
- 2005-11-28 KR KR1020097018388A patent/KR101244362B1/ko active IP Right Grant
- 2005-11-28 NZ NZ555075A patent/NZ555075A/en not_active IP Right Cessation
- 2005-11-28 WO PCT/IN2005/000382 patent/WO2006059344A1/en active Application Filing
- 2005-11-28 PT PT05817957T patent/PT1841432E/pt unknown
- 2005-11-28 DK DK05817957.3T patent/DK1841432T3/da active
- 2005-11-28 AU AU2005310888A patent/AU2005310888B2/en not_active Ceased
- 2005-11-28 AT AT05817957T patent/ATE476981T1/de active
- 2005-11-28 CN CNA2005800395645A patent/CN101060846A/zh active Pending
- 2005-11-28 RS RSP-2010/0465A patent/RS51506B/en unknown
-
2007
- 2007-05-29 ZA ZA200704394A patent/ZA200704394B/xx unknown
-
2010
- 2010-11-03 HR HR20100591T patent/HRP20100591T1/hr unknown
- 2010-11-10 CY CY20101101012T patent/CY1110886T1/el unknown
-
2012
- 2012-09-25 US US13/626,236 patent/US9012442B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100160277A1 (en) | 2010-06-24 |
| AU2005310888A1 (en) | 2006-06-08 |
| US20130023512A1 (en) | 2013-01-24 |
| US9012442B2 (en) | 2015-04-21 |
| PT1841432E (pt) | 2010-10-25 |
| ES2349301T3 (es) | 2010-12-29 |
| US8273732B2 (en) | 2012-09-25 |
| ZA200704394B (en) | 2008-09-25 |
| RU2007124325A (ru) | 2009-01-10 |
| EP1841432A1 (en) | 2007-10-10 |
| RS51506B (en) | 2011-06-30 |
| NZ555075A (en) | 2011-02-25 |
| SI1841432T1 (sl) | 2011-02-28 |
| KR20070067189A (ko) | 2007-06-27 |
| CY1110886T1 (el) | 2015-06-10 |
| JP5269415B2 (ja) | 2013-08-21 |
| EP1841432B1 (en) | 2010-08-11 |
| DE602005022939D1 (de) | 2010-09-23 |
| PL1841432T3 (pl) | 2011-01-31 |
| BRPI0517128A (pt) | 2008-09-30 |
| JP2008521884A (ja) | 2008-06-26 |
| WO2006059344A1 (en) | 2006-06-08 |
| UA91204C2 (ru) | 2010-07-12 |
| MX2007006540A (es) | 2008-01-31 |
| ATE476981T1 (de) | 2010-08-15 |
| AU2005310888B2 (en) | 2011-01-06 |
| WO2006059344B1 (en) | 2006-11-02 |
| KR101244362B1 (ko) | 2013-03-18 |
| KR20090101514A (ko) | 2009-09-28 |
| DK1841432T3 (da) | 2010-12-06 |
| RU2397768C2 (ru) | 2010-08-27 |
| CN101060846A (zh) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100591T1 (hr) | Smjese za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije | |
| US11872266B2 (en) | Rapid-acting insulin compositions | |
| JP2008521884A5 (hr) | ||
| US20190216842A1 (en) | Vitamin b12 nasal spray and method of use | |
| JP2008530082A5 (hr) | ||
| HRP20231151T1 (hr) | Režimi za doziranje spojeva iz klase ehinokandina | |
| RU2007101686A (ru) | Комбинированная композиция | |
| PE20050438A1 (es) | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos | |
| KR101120971B1 (ko) | 주사용 조성물 | |
| NZ541533A (en) | Liquid pharmaceutical formulations of palonosetron | |
| BRPI0612447A2 (pt) | composição antibiótica de dose fixa, processo para a preparação de um produto de combinação antibiótica de dose fixa, processo para a preparação de uma injeção lìquida e usos de pó seco para injeção e injeção lìquida | |
| JP2013509435A5 (hr) | ||
| KR20140025314A (ko) | 복합 조성물 | |
| CN1396828A (zh) | 含有培美西德以及一硫代甘油l－半胱氨酸或巯乙酸的药物组合物 | |
| KR20070101292A (ko) | 분무기 제제 | |
| CA2802303A1 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| US3634586A (en) | Stable aqueous suspensions of ampicillin | |
| EP1166773B1 (en) | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | |
| AU2011274652A1 (en) | A combination composition comprising ibuprofen and paracetamol | |
| JP2018048096A (ja) | 液体製剤、及び、パロノセトロンの安定性を向上する方法 | |
| US11925703B1 (en) | Liquid composition comprising glucose | |
| CA3201498A1 (en) | Compositions comprising flumazenil and naltrexone and methods for use thereof | |
| US5997884A (en) | Compositions and method for treating migraine | |
| JPH02172919A (ja) | アスピリン―ｄｌ―リジン粉末注射剤 | |
| TH13160A (th) | วิธีการผลิตกลูตาไธโอนที่มีขนาดยาสูงยาเม็ดและยาหลอดที่ผลิตโดยวิธีนี้ |